




RealRate

PHARMACEUTICAL 2020

NeuroBo Pharmaceuticals Inc.
Rank 330 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2020

NeuroBo Pharmaceuticals Inc. Rank 330 of 362

The relative strengths and weaknesses of NeuroBo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NeuroBo Pharmaceuticals Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 101% points. The greatest weakness of NeuroBo Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 546% points.

The company's Economic Capital Ratio, given in the ranking table, is -877%, being 574% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	14,118
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,082
Liabilities, Non-Current	0
Other Assets	150
Other Compr. Net Income	10
Other Expenses	0
Other Liabilities	94
Other Net Income	-1,136
Property and Equipment	200
Research and Development	17,475
Revenues	0
Selling, General and Administrative Expense	2,701

Output Variable	Value in 1000 USD
Assets	14,468
Liabilities	2,176
Expenses	20,176
Stockholders Equity	12,292
Net Income	-21,312
Comprehensive Net Income	-21,307
Economic Capital Ratio	-877%

